سعر سبيروميترو 30 اقراص 2024

Spirometro film-coated tablets (El-Obour, Egypt), pack of 30: combination of metronidazole and spiramycin (listed as 250 mg + 1.5 MIU), used for selected oral and dental infections.

• Curative treatment of odonto-stomatological infections such as dental abscesses, in adults and children, after assessing the benefit-risk of this fixed spiramycin-metronidazole combination and when another antibiotic cannot be used.Population: Adults and children over 15 years (posology)Asafar (Moroccan medicines database based on AMMPS/ANAM data)

• Metronidazole: epigastric pain, nausea, vomiting, diarrhoea, oral mucositis, taste disturbance, anorexia, reversible pancreatitis, tongue discoloration; angioedema, anaphylactic shock; peripheral sensory neuropathy, headache, convulsions, vertigo, encephalopathy, acute cerebellar syndrome, aseptic meningitis; psychotic disorder, confusion, hallucinations; transient visual disturbances, optic neuropathy; agranulocytosis, neutropenia, thrombocytopenia; raised liver enzymes, cholestatic or mixed hepatitis, liver failure; rash, pruritus, urticaria, pustular eruptions, Stevens-Johnson syndrome, toxic epidermal necrolysis; fever.General active-ingredient information · Vademecum (Vidal Vademecum Spain; Egypt drug database)

• Metronidazole: hypersensitivity to imidazoles.General active-ingredient information · Vademecum (Vidal Vademecum Spain; Egypt drug database)

• The fixed spiramycin-metronidazole combination should be used only after benefit-risk assessment and when another antibiotic treatment cannot be used; official recommendations on appropriate antibacterial use apply.International label, same formulation · Asafar (Moroccan medicines database based on AMMPS/ANAM data)
• Metronidazole: risk of neurological worsening in severe acute or chronic central or peripheral nervous system disease; if treatment must be prolonged, weigh benefit-risk, perform blood counts (especially leucocytes) and watch for central or peripheral neuropathy.General active-ingredient information · Vademecum (Vidal Vademecum Spain; Egypt drug database)
• Metronidazole: disulfiram-like (antabuse) effect with alcohol, avoid alcohol; darkens urine; severe hepatotoxicity/acute liver failure (including a fatal case) reported in patients with Cockayne syndrome - do not use unless no alternative, and then monitor liver function closely.General active-ingredient information · Vademecum (Vidal Vademecum Spain; Egypt drug database)

• DisulfiramPsychotic reaction with metronidazole; stop disulfiram 2 weeks before treatment.Vademecum (Vidal Vademecum Spain; Egypt drug database)
• AlcoholDisulfiram-like (antabuse) effect with metronidazole; avoid alcohol.Vademecum (Vidal Vademecum Spain; Egypt drug database)
• Oral anticoagulantsMetronidazole reduces their hepatic metabolism and potentiates their effect; adjust dose and monitor prothrombin time.Vademecum (Vidal Vademecum Spain; Egypt drug database)

• Use may be considered during pregnancy if needed, whatever the term: analysis of a large number of exposed pregnancies showed no particular malformative or foetotoxic effect of metronidazole (only epidemiological studies could confirm absence of risk; no teratogenicity in animals), and wide use of spiramycin in pregnancy has not shown malformative or foetotoxic effects.International label, same formulation · Asafar (Moroccan medicines database based on AMMPS/ANAM data)
• Metronidazole and spiramycin pass into breast milk; avoid administration during breastfeeding.International label, same formulation · Asafar (Moroccan medicines database based on AMMPS/ANAM data)

• Metronidazole: Nitroimidazole: reduced intracellularly in anaerobic and microaerophilic bacteria and protozoa; the reduction product disrupts DNA and inhibits its synthesis (bactericidal).
• Spiramycin: Macrolide: binds the 50S subunit of bacterial ribosomes, blocking transpeptidation and inhibiting protein synthesis; primarily bacteriostatic, possibly bactericidal against more sensitive strains at high concentrations.